Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. - Test2 - elhamkhani - TriplyDB

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

http://www.wikidata.org/entity/Q37112901

about

Current Trends of Renal Impairment in Multiple Myeloma Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.Bortezomib, dexamethasone plus thalidomide for treatment of newly diagnosed multiple myeloma patients with or without renal impairment.Case report on renal failure reversal in lambda chain multiple myeloma with bortezomib and dexamethasone.Prognostic value of cystatin C in patients with nasopharyngeal carcinoma: a retrospective study of 1063 patients.Cystatin C and lactoferrin concentrations in biological fluids as possible prognostic factors in eye tumor development.Evaluation of serum procathepsin B, cystatin B and cystatin C as possible biomarkers of ovarian cancer Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry.Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.Management of myeloma-associated renal dysfunction in the era of novel therapies.Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.Confident assignment of intact mass tags to human salivary cystatins using top-down Fourier-transform ion cyclotron resonance mass spectrometry Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcome.Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EP Bortezomib for the treatment of multiple myeloma.Prognostic significance of serum cystatin C in multiple myeloma.Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma

P2860

Q26740444-DDFCCE19-0C7C-405F-98D1-0A99065FB8A2 Q33397490-7DBA6832-5486-4C56-81CE-F16A54739ADB Q33407105-133AAA63-2D8D-440F-B261-982F5B66FC59 Q33874209-91C728C6-F591-4C60-97A2-19CCF6AC57C0 Q37059721-DA25F21E-2263-4F07-9CA6-1DA3A1B63100 Q37120573-8AA2551E-BC24-47B1-AA20-CA0AFD622B4B Q37124662-06AA5513-11A5-4A75-9004-EF6A93B3497A Q37710444-B3C006B5-1B53-4844-B0AA-C5FA5DF16AF2 Q37761370-B6E8FB6D-3106-4FEF-8A8C-D8CB3C6B0B9B Q37978343-5B106FAE-747B-4E45-8F56-7D64D3196E18 Q40261261-0F19DD0B-16D0-4125-8E48-32AC532DE4E5 Q40640909-E21BC04C-6E61-42EC-BDF9-3FF33C5F6193 Q43005372-3E4FF742-A85A-473E-ABBF-67D7203A9337 Q43106531-1DE5104E-F725-4946-8F58-07589CDC10CA Q45787936-D5BEC332-93E3-47A0-AA84-B60805271322 Q47604607-9E64B1C0-314C-4070-A162-FE37561E248C Q48008982-FAB463C9-07BF-474D-A9B0-1D8FD3CB0337 Q58762704-95025169-410F-4673-9444-FE561954813C

P2860

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

http://www.wikidata.org/entity/Q37112901

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cystatin-C is an independent p ...... by bortezomib administration.

@en

Cystatin-C is an independent p ...... by bortezomib administration.

@nl

type

label

Cystatin-C is an independent p ...... by bortezomib administration.

@en

Cystatin-C is an independent p ...... by bortezomib administration.

@nl

prefLabel

Cystatin-C is an independent p ...... by bortezomib administration.

@en

Cystatin-C is an independent p ...... by bortezomib administration.

@nl

P1433

Q37112901-0975F924-B76E-497D-B16F-01C6D43C3099

P1476

Q37112901-DD81400F-5826-4F84-A2EA-D4BD6CA5F235

P2093

Q37112901-06FB51BA-470A-425D-B7B3-D3C4A37D6298

Q37112901-0C3F647B-C93A-41BC-A0E8-C862FD1CBCD5

Q37112901-194B3B93-2723-4936-B437-DE436280A031

Q37112901-59346E85-30D8-47CB-B413-92F5E62CD8B7

Q37112901-6ECD7628-632B-4155-AD79-E929F004501D

Q37112901-70A77570-120D-41E6-9D4B-CCF33C670091

Q37112901-8A96E264-B192-4683-A232-7CB41B770FFE

Q37112901-8B5CB67B-BDCC-42AB-A614-D17D1D8C8573

Q37112901-9E66B6A7-8F52-41C6-B5AA-73A32E12FF9E

Q37112901-ACF77427-81AB-43FA-8DB4-3A5EBA227FE7

P2860

Q37112901-1E9EEBC7-6CBC-44A7-A4B7-7BC48C965A87

Q37112901-20C66100-C938-4DB7-9651-9400F1964EF8

Q37112901-3F553752-0983-4D74-9440-4DEF5911E822

Q37112901-402DD2F6-A7B1-45D4-BD7F-D3B81AEA3BEB

Q37112901-435679C9-9228-4906-9102-B57CEEB4B436

Q37112901-4CACBA96-4C43-4EEA-BFBF-75A5A92AFB14

Q37112901-542A5A56-0A9B-4D19-A03F-B937F468A8E7

Q37112901-557641AB-4D4F-413B-A6FD-5AF02DC5967A

Q37112901-5C5E9CAD-1804-4660-A7CA-E204C697D196

Q37112901-603F3318-CC01-455F-9A8F-7D09E4B44F0D

P304

Q37112901-95964907-1963-4211-81A2-08C32F736C2E

P31

Q37112901-DD12BC56-8EEF-43D9-B386-811335A6C13B

P356

Q37112901-C8AA4E2F-01DC-46F5-A6B4-0710D1222282

P433

Q37112901-9DD0BCC4-9419-4272-A4D3-149A7F410E7C

P478

Q37112901-25A8CBAE-7775-4750-93B2-829F4E45AFE1

P50

Q37112901-5469EDB3-797A-472F-834C-9E06FA73CB0C

Q37112901-9F87C349-1E2C-4672-B006-9A12F7F78146

P577

Q37112901-5DBB3CA3-5BE0-464E-AC63-95E32BE001D9

P5875

Q37112901-9FA9EBB1-1F0A-44DF-9BC4-16B03ED444A3

P698

Q37112901-29C99556-F07C-4F0A-9C64-CA3FD955B229

P932

Q37112901-6F73D5BD-0046-40E9-87CF-94295B10C4B0

P356

HAEMATOL.2008.000638

P1433

P1476

Cystatin-C is an independent p ...... by bortezomib administration.

@en

P2093

Anastasia Pouli

http://www.w3.org/2001/XMLSchema#string

Dimitrios Christoulas

http://www.w3.org/2001/XMLSchema#string

Eirini Katodritou

http://www.w3.org/2001/XMLSchema#string

Eurydiki Michalis

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Evangelos Tsiftsakis

http://www.w3.org/2001/XMLSchema#string

Evgenia Verrou

http://www.w3.org/2001/XMLSchema#string

Greek Myeloma Study Group

http://www.w3.org/2001/XMLSchema#string

Konstantinos Anargyrou

http://www.w3.org/2001/XMLSchema#string

Konstantinos Tsionos

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and expression of the human cystatin C gene

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD

Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study

Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients

Effect of corticosteroid therapy on serum cystatin C and beta2-microglobulin concentrations

Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis

Thyroid function differently affects serum cystatin C and creatinine concentrations

Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression

Cystatin C as a marker of GFR--history, indications, and future research

Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate

P304

372-379

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2008.000638

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Efstathios Kastritis

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24146712

http://www.w3.org/2001/XMLSchema#string

P698

19252175

http://www.w3.org/2001/XMLSchema#string

P932

2649362

http://www.w3.org/2001/XMLSchema#string